{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"3.7","value":"3.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"PFS defined as the time from the date of the first dose of the study drug to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause according to Investigator assessment","dispersionType":"95% Confidence Interval","groups":[{"description":"260 mg once daily (QD) orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle","id":"OG000","title":"Milademetan (RAIN-32)"}],"paramType":"MEDIAN","populationDescription":"The efficacy analysis is conducted in all participants within the Centrally confirmed population (CCP).","reportingStatus":"POSTED","timeFrame":"From the first dose date to the earliest date of recurrence, progression, death, or study completion; up to 23.5 months","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}